OUR APPROACH: CONDITIONALLY ACTIVATED IMMUNOTHERAPY

WTX-330x2101 FIRST-IN-HUMAN STUDY DESIGN
Investigating WTX-330 as a monotherapy

**DOSE ESCALATION**
- Immunomodulatory cytokine
- Cytokine domain
- Inflammation domain
- Tumor-IGF domain
- Half-life extension domain

**DOSE EXPANSION ARM A**
- 1.5x validated for which ICIs are approved
- Primary ICI: nivolumab
- Patients with ≥ 1 line of prior therapy

**DOSE EXPANSION ARM B**
- 1.5x validated for which ICIs are approved
- Primary ICI: pembrolizumab
- Patients with ≥ 1 line of prior therapy

**PRIORITY ICI RESISTANCE:**
- Non-small cell lung cancer

**SECONDARY ICI RESISTANCE:**
- PD-L1 high tumors
- BRCA1/BRCA2
- Germline or somatic DNA damage

**STUDY OBJECTIVES AND ENDPOINTS**

**OBJECTIVES**
- Evaluate safety and tolerability
- Assess biomarker maximum tolerated dose
- Evaluate antitumor activity and overall response rate

**ENDPOINTS**
- Ipsilateral breast recurrence (iRECIST)
- 30-day mortality
- Overall survival (OS)

**ACTIVE STUDY SITE:**
- Assembling a world-class team of clinical investigators

**SUMMARY AND CONCLUSIONS**
- An unmet medical need exists for patients with cancer who demonstrate primary or secondary resistance to standard of care ICI regimens, and for patients with tumor types for which ICIs are not approved
- WTX-330 is an IL-12 INDIKINE™ molecule that uses a prodrug strategy to leverage the favorable proinflammatory activities of this potent and pleiotropic cytokine to safely stimulate antitumor immune responses
- Enrollment in the dose escalation part of the WTX-330x2101 first-in-human study is presently ongoing

**CLINICAL TRIAL PAGE:**
- https://clinicaltrials.gov/ct2/show/NCT04979529

**TRANSLATIONAL BIOMARKER STRATEGY**
Interrogating antitumor immune activation in patients

**Biomarker (Blood)**
- Key question addressed: Does WTX-330 affect immune cell frequency and/or immunophenotype?
- Method: Flow cytometry

**Biomarker (Tumor)**
- Key question addressed: Does WTX-330 affect immune cell frequency and/or immunophenotype?
- Method: Flow cytometry

**Biomarker (Serum)**
- Key question addressed: Does WTX-330 affect serum cytokine levels?
- Method: Flow cytometry

**PATIENT POPULATIONS**

**STUDY SETTINGS**
- 1. NextOncology (San Antonio, TX)
- 2. Hershey Medical Center (Hershey, PA)
- 3. Siteman Cancer Center at Washington University (St Louis, MO)
- 4. Massachusetts General Hospital (Boston, MA)
- 5. Northwestern Feinberg School of Medicine (Chicago, IL)
- 6. UPMC Hillman Cancer Center (Pittsburgh, PA - Jimmy S. "Jim" Thompson Cancer Research Institute)

**HUMAN STUDY DESIGN**
- Investigate WTX-330 as a monotherapy

**BIOMARKER STRATEGY**
- Interrogating antitumor immune activation in patients

**TRANSLATIONAL BIOMARKER STRATEGY**
- Interrogating antitumor immune activation in patients

**Biomarker (Blood)**
- Key question addressed: Does WTX-330 affect immune cell frequency and/or immunophenotype?
- Method: Flow cytometry

**Biomarker (Tumor)**
- Key question addressed: Does WTX-330 affect immune cell frequency and/or immunophenotype?
- Method: Flow cytometry

**Biomarker (Serum)**
- Key question addressed: Does WTX-330 affect serum cytokine levels?
- Method: Flow cytometry

**STUDY OBJECTIVES AND ENDPOINTS**

**OBJECTIVES**
- Evaluate safety and tolerability
- Assess biomarker maximum tolerated dose
- Evaluate antitumor activity and overall response rate

**ENDPOINTS**
- Ipsilateral breast recurrence (iRECIST)
- 30-day mortality
- Overall survival (OS)

**ACTIVE STUDY SITE:**
- Assembling a world-class team of clinical investigators

**SUMMARY AND CONCLUSIONS**
- An unmet medical need exists for patients with cancer who demonstrate primary or secondary resistance to standard of care ICI regimens, and for patients with tumor types for which ICIs are not approved
- WTX-330 is an IL-12 INDIKINE™ molecule that uses a prodrug strategy to leverage the favorable proinflammatory activities of this potent and pleiotropic cytokine to safely stimulate antitumor immune responses
- Enrollment in the dose escalation part of the WTX-330x2101 first-in-human study is presently ongoing

**CLINICAL TRIAL PAGE:**
- https://clinicaltrials.gov/ct2/show/NCT04979529